FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
8 letters match. Newest first.
-
DrugsFresenius Kabi USA LLC
FDA warns Fresenius Kabi USA over manufacturing failures for sterile injectables at Melrose Park, including endotoxin contamination and media fill failures.
High risk -
DrugsBausch & Lomb Inc.
FDA warns Bausch & Lomb of persistent microbial contamination and poor aseptic controls at its Tampa sterile drug plant.
High risk -
DrugsK.C. Pharmaceuticals, Inc.
FDA cited K.C. Pharmaceuticals of Pomona, CA, for sterile-drug manufacturing failures, including aseptic practice problems and failed media fills.
High risk -
DrugsSomerset Therapeutics Private Limited
FDA cited Somerset Therapeutics' India plant for CGMP failures tied to a contaminated media fill and aseptic processing risks.
High risk -
DrugsAnnovex Pharma, Inc.
FDA warns outsourcing facility Annovex Pharma in Lorton, VA, over contaminated sterile drug production and missed FDA reports.
High risk -
DrugsEugia Pharma Specialities Limited
FDA cited Eugia Pharma Specialities for CGMP violations at its India sterile injectable plant, including falsified records and contamination risks.
High risk -
DrugsK.C. Pharmaceuticals Inc.
FDA warned K.C. Pharmaceuticals after inspections found manufacturing rule violations in sterile ophthalmic drugs, including inadequate contamination controls and cleaning validation.
High risk -
DrugsAbraxis Bioscience LLC
FDA warned Abraxis Bioscience about repeated contamination in media fills for sterile Abraxane at its Phoenix plant.
High risk